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1. Introduction  
Vitiligo is an idiopathic disorder of pigmentation characterised by the presence of 
depigmented skin macules due to the chronic and progressive loss of melanocytes from the 
cutaneous epidermis. Large population surveys have shown a worldwide incidence of 1-2% 
(Boisseau-Garsaud et al., 2000; Howitz et al., 1977; Majumder et al. 1993; Mehta et al., 1973), 
although a prevalence of 8.8% has been reported in India (Sehgal & Srivastava, 2007). The 
disease occurs independently of age and race, and both sexes are equally affected (Behl et 
al., 2003; Cho et al., 2000; Handa & Dogra, 2003; Hann & Lee, 1996; LePoole & Boissy, 1997; 
Zaima & Koga, 2002). In approximately half of all cases, vitiligo appears before the age of 20 
years, and 70-80% of patients develop the disease by the age of 30 years (Behl et al., 2003; 
Herane, 2003). Frequently, patients with vitiligo also suffer from other autoimmune 
conditions (Alkhateeb et al., 2003; Laberge et al., 2005). 
Usually, vitiligo is viewed as a minor disease, but the impact on patients’ psychological 
well-being and social interactions is often underestimated (Kent & Al’ Abadie, 1996; 
Ongenae et al., 2006; Porter et al., 1986). The treatment of choice in vitiligo is dependent 
upon factors which include vitiligo type (non-segmental, segmental), patient age, and 
location and stability of depigmented lesions (Taieb & Picardo, 2010). However, despite the 
many available therapeutic modalities (Abu Tahir et al., 2010; Olsson, 2010), repigmentation 
in the majority of vitiligo patients is rarely complete or long-lasting, so a better 
understanding of the precise aetiology and pathogenesis of the disease is crucial to 
improving the efficacy of treatment regimens. 
Currently, the exact aetiology of vitiligo remains obscure, but many factors have been 
implicated in the development of the disease including infections (Grimes et al., 1996; Shegan, 
1971), stress (Al'Abadie et al., 1994a), neural abnormalities (Al'Abadie et al., 1994b), defective 
melanocyte adhesion (Gauthier et al., 2003), and genetic susceptibility (Spritz, 2010). The 
biochemical hypothesis argues that melanocyte destruction is due to the accumulation of toxic 
metabolites from melanogenesis, the break-down of free-radical defence and an excess of 
hydrogen peroxide (Dell’Anna & Picardo, 2006; Schallreuter et al., 1991; Schallreuter et al., 
2001; Schallreuter et al., 2005). In addition, many studies have indicated a role for both cellular 
(Ogg et al., 1998; Van den Boorn et al., 2009; Wankowicz-Kalinska et al., 2003) and humoral 
(Gilhar et al., 1995; Naughton et al., 1983a; Norris et al., 1988a) immunity in the pathogenesis of 
vitiligo. Ultimately, these different factors may act independently or together to yield the same 
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effect, namely the disappearance of melanocytes from the skin and this is proposed in the 
convergence theory (Le Poole et al., 1993a). For example, autoimmunity might arise as a 
secondary phenomenon following the self-destruction of pigment cells and this might then 
amplify the damage to melanocytes. In addition, different pathogenic mechanisms could 
account for the various clinical types of vitiligo:  the possible neural mechanisms are usually 
related to segmental vitiligo, whereas autoimmunity is most often associated with the non-
segmental (generalised) form (Taieb, 2000).  
2. Immunological factors in vitiligo aetiology and pathogenesis 
The evidence for the role of autoimmunity in the aetiology and pathogenesis of vitiligo will 
be discussed in the next sections. 
2.1 Immuno-genetic factors 
The majority of cases of vitiligo are sporadic without a family history of the disease. 
Nevertheless, 15-20% of patients report at least one affected first-degree relative (Alkhateeb 
et al., 2003), lending evidence for a genetic role in the aetiology of vitiligo. Furthermore, 
among Caucasians, the risk of vitiligo developing in a patient’s sibling is approximately 
6.1% (Alkhateeb et al., 2003), an increase of 16-fold compared to the general Caucasian 
population where the prevalence of the disease is 0.38% (Howitz et al., 1977). Similarly, an 
increased risk among first-degree relatives is found in Indian-Pakistanis at 6.1% (Alkhateeb 
et al., 2003), in American Hispanic-Latinos at 4.8% (Alkhateeb et al., 2003) and in Han 
Chinese at 2.6% (Sun et al., 2006). A simple Mendelian inheritance pattern is not displayed 
in these familial aggregations of vitiligo cases (Alkhateeb et al., 2003; Bhatia et al., 1992; 
Carnevale et al., 1980; Das et al., 1985; Hafez et al., 1983; Laberge et al., 2005; Majumder et 
al., 1988; Majumder et al., 1993; Mehta et al., 1973; Nath et al., 1994; Sun et al., 2006), 
suggesting that the disease is probably transmitted as a polygenic trait. Indeed, earlier 
disease onset in familial cases (Alkhateeb et al., 2003; Laberge et al., 2005) and reduced risk 
of vitiligo with increasing genetic distance from the patient (Alkhateeb et al. 2003) are 
indicative of a polygenic disorder. Formal genetic segregation analyses of vitiligo have also 
suggested that multiple loci contribute to vitiligo susceptibility (Majumder et al., 1993; Nath 
et al., 1994; Sun et al., 2006). Seldomly have large multi-generation families been reported 
where vitiligo segregates in an autosomal dominant pattern (Alkhateeb et al., 2005). Twin 
studies have also provided evidence of a genetic component to vitiligo aetiology. For vitiligo 
in monozygotic twins, the concordance is 23% (Alkhateeb et al. 2003), a disease risk that is 
60-fold greater than that in the general population (Howitz et al., 1977) and 4-fold higher 
than that for a patient’s sibling (Alkhateeb et al., 2003). 
The genetic epidemiological evidence has prompted the search for genes which predispose 
an individual to vitiligo. Investigations have included families with vitiligo as well as 
cohorts of patients without a familial history of the disease (Cantón et al., 2005; Fain et al., 
2003). In addition, different approaches have been employed to identify genes which confer 
susceptibility to vitiligo including candidate gene association studies (Blomhoff et al., 2005; 
Cantón et al., 2005), genome-wide linkage studies (Chen et al., 2005; Fain et al., 2003; Liang 
et al., 2007; Spritz et al., 2004), and genome-wide association studies (Birlea et al., 2010; Jin et 
al., 2010a; Quan et al., 2010). The majority of genes and genetic loci so far identified have a 
role in the function of the immune system (Spritz, 2010), and these are summarised in the 
following sections. 
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2.1.1 Human leukocyte antigen alleles of the major histocompatibility complex 
Initial case-control analyses demonstrated an association between predisposition to vitiligo 
and several different human leukocyte antigen (HLA) alleles of the major histocompatibility 
complex (MHC), and these are summarised in Table 1. Although these studies showed weak 
and variable associations, a significant association of HLA-DR4 and vitiligo was 
demonstrated in several populations (Dunston et al. 1990; Foley et al. 1983; Venneker et al. 
1992) and a subsequent meta-analysis of a series of case-control studies reported association 
of vitiligo with HLA-A2 (Liu et al., 2007). 
 
Population 
 
Associated HLA Allele  Reference 
American (Caucasian) DR4 Foley et al., 1983 
American (African) DR4, DQw3  Dunston et al., 1990 
American and British 
(European-derived, 
Caucasian)  
DRB1A*04-DQB1*0301 Fain et al., 2006 
American and British 
(European-derived, 
Caucasian)  
Class I (specifically A*0201) and II 
antigens 
Jin et al., 2010a 
Chinese (Han) DQA1*0302, DQB1*0303, 
DQB1*0503 
Yang et al., 2005 
Chinese (Han) A25-Cw*0602-DQA1*0302 Xia et al., 2006 
Chinese (Han and 
Uygar) 
Class I and II antigens Quan et al., 2010 
Dutch DR4, DR6, Cw6 Venneker et al., 1993; 
Venneker et al., 1992 
Dutch DRB4*0101, DQB1*0303 Zamani et al., 2001 
German (Northern) A2 Schallreuter et al., 1993 
Hungarian DR1, DR3 Poloy et al., 1991 
Italian A30, B27, Cw6, DQw3 Finco et al., 1991 
Italian (Northern) A3 Lorini et al., 1992 
Italian (Northern) A30, Cw6, DQw3  Orecchia et al., 1992 
Japanese A31, Bw46, Cw4 Ando et al., 1993 
Kuwaiti  B21, Cw6 Al-Fouzan et al., 1995 
Moroccan (Jewish) B13 Metzker et al., 1980 
Omani Bw6, DR7  Venkataram et al., 1995 
Slovak A2, Dw7 Buc et al., 1996 
Turkish DRB1*03, DRB1*04, DRB1*07 Tastan et al., 2004 
Yemeni  Bw35  Metzker et al., 1980 
Table 1. Association of human leukocyte antigen (HLA) alleles with vitiligo susceptibility  
More recently, the use of better analytical and statistical methods has revealed associations 
of vitiligo with HLA-DRB1*04, HLA-DRB1*03 and HLA-DRB1*07 alleles in Turkish patients 
(Tastan et al., 2004), with HLA-DRB4*0101 and HLA-DQB1*0303 in Dutch patients (Zamani 
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et al., 2001), and HLA-A25-Cw*0602-DQA1*0302, HLA-DQA1*0302, HLA-DQB1*0303 and 
HLA-DQB1*0503 in Han Chinese patients (Xia et al., 2006; Yang et al., 2005). Furthermore, a 
study of 76 Caucasian multiplex vitiligo families found the HLA-DRB1A*04-DQB1*0301 
haplotype to be associated with a higher risk of developing vitiligo and with an earlier onset 
of the disease (Fain et al., 2006). Finally, two genome-wide association studies undertaken 
on populations of vitiligo patients have reported that predisposition of vitiligo is associated 
with HLA class I and II antigens (Jin et al., 2010a; Quan et al., 2010). 
2.1.2 Immune-response genes and loci 
Variations in several immune-response genes, including CCR6, FOXP1, FOXP3, TSLP and 
XBP1, have a confirmed association with predisposition to vitiligo and these are summarised in 
Table 2 (Birlea et al., 2011; Cheong et al., 2009; Jin et al., 2010a; Jin et al., 2010b; Quan et al., 2010; 
Ren et al., 2009). Of particular note, the allelic variation R620W of the PTPN22 gene, which 
encodes lymphoid protein tyrosine phosphatase, a molecule involved in T cell signalling, has 
been shown to confer vitiligo susceptibility in several independent reports (Cantón et al., 2005; 
Jin et al., 2010a; Laberge et al., 2008a; Laberge et al., 2008b). In addition, allelic variants in the 
NLRP1 gene (previously NALP1 or SLEV1), which encodes a key regulator of the innate 
immune system, have been reproducibly associated with an increased risk of vitiligo in 
different populations (Jin et al., 2007a; Jin et al., 2007b; Nath et al., 2001; Spritz et al., 2004).  
The study of variations in the cytotoxic T lymphocyte antigen 4 (CTLA4) gene has yielded 
conflicting results with respect to vitiligo susceptibility (Birlea et al., 2011; Birlea et al., 2009; 
Blomhoff et al., 2005; Deeba et al., 2010; Itirli et al., 2005; Kemp et al., 1999; Laberge et al., 
2008a; Pehlivan et al., 2009). Presently, allelic differences in CTLA4 appear to be 
predominantly associated with vitiligo occurring together with other autoimmune diseases 
(Blomhoff et al., 2005), and it has been suggested, therefore, that the association of CTLA4 
with vitiligo is probably secondary to its primary association with disorders such as 
autoimmune thyroid disease (Spritz, 2010).  
2.2 Associated autoimmune disease 
Vitiligo is frequently associated with other autoimmune disorders, particularly autoimmune 
thyroid disease (Boelaert et al., 2010; Ochi & DeGroot, 1969), autoimmune polyendocrine 
syndromes (Ahonen et al., 1990; Neufeld et al., 1990), pernicious anaemia (Dawber, 1970), 
Addison’s disease (Zelissen et al., 1995), and alopecia areata (Ahmed et al., 2007). 
Furthermore, patients with vitiligo are more likely to suffer from autoimmune conditions 
than those in the general population (Birlea et al., 2008; Cunliffe et al., 1968; Liu et al., 2005; 
Turnbridge et al., 1977). In a survey of more than 2,600 unselected Caucasian vitiligo 
patients, elevated frequencies of autoimmune thyroid disease, Addison’s disease, systemic 
lupus erythematosus and pernicious anaemia were found, with approximately 30% of 
patients being affected with at least one additional autoimmune disorder (Alkhateeb et al., 
2003). Moreover, these same autoimmune diseases occurred at an increased frequency in the 
first-degree relatives of the patients studied (Alkhateeb et al., 2003). Similarly, in multiplex 
generalised vitiligo families, higher frequencies of psoriasis, rheumatoid arthritis and type 1 
diabetes mellitus were noted in addition to autoimmune thyroid disease, Addison’s disease, 
systemic lupus erythematosus and pernicious anaemia (Laberge et al., 2005). Such data 
indicate that individuals can be genetically predisposed to a specific group of autoimmune 
diseases that includes vitiligo, and are also evidence for an autoimmune aetiology for this 
depigmenting disorder. 
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Gene or Locus 
 
Function/Comment Reference 
AIS2 
 
Autoimmune susceptibility locus 2. Function 
undefined. Associated with autoimmune disease. 
Spritz et al., 2004 
CCR6 
 
Cytokine-chemokine receptor for CCL20. Recruits 
immune cells on binding of ligand. Associated 
with inflammatory bowel disease. 
Jin et al., 2010a; Jin et 
al., 2010b; Quan et al., 
2010 
C1QTNF6 
 
C1q and tumour necrosis factor-related protein- 6. 
Associated with rheumatoid arthritis and type 1 
diabetes mellitus. 
Jin et al., 2010a 
FOXP1 Forkhead box P1. Transcription factor which 
regulates development of immune cells.  
Jin et al., 2010a; Jin et 
al., 2010b 
FOXP3 Forkhead box P3. Transcription factor which 
regulates regulatory T cell development. Causes 
autoimmune IPEX syndrome. 
Birlea et al., 2011 
GZMB 
 
Granzyme B. Regulates cell-mediated immune 
responses. 
Jin et al., 2010a 
IL2RA 
 
Interleukin (IL)-2 receptor alpha chain. Receptor 
for cytokine IL2 which induces T and B cell 
proliferation. Associated with many autoimmune 
diseases. 
Jin et al., 2010a 
LPP 
 
LIM domain-containing preferred translocation 
partner in lipoma. Function unknown. Associated 
with celiac disease and rheumatoid arthritis. 
Jin et al., 2010a 
NLRP1 (NALP1; 
SLEV1) 
 
NACHT leucine-rich-repeat protein 1. Functions 
in the innate immune response. Associated with 
many autoimmune diseases. 
Jin et al., 2007a; Jin et 
al., 2007b; Nath et al., 
2001; Spritz et al., 
2004 
PTPN22 
 
Lymphoid protein tyrosine phosphatase. 
Negatively regulates T cell activation. Associated 
with many autoimmune diseases. 
Cantón et al., 2005; 
Jin et al., 2010a; 
Laberge et al., 2008a; 
Laberge et al., 2008b 
TSLP Thymic stromal lymphopoietin. Cytokine which 
induces naïve CD4+ T cells to produce T helper 
cell 2 cytokines.  
Birlea et al., 2011; 
Cheong et al., 2009 
UBASH3A Ubiquitin-associated and SH3 domain-containing 
A gene. Regulates T cell receptor signalling. 
Associated with type 1 diabetes mellitus. 
Jin et al., 2010a 
XBP1 
 
X-box binding protein 1. Transcription factor 
which regulates MHC class II gene expression. 
Associated with inflammatory bowel disease. 
Birlea et al., 2011; Ren 
et al., 2009 
Table 2. Confirmed associations of immune-response gene variants with vitiligo 
susceptibility 
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2.3 Animal models  
The study of animal models has added credence to the theory that immune mechanisms 
play a part in the development of vitiligo. Several spontaneous animal models of vitiligo 
exist, although the exact relevance of such models to the equivalent human disorder remains 
to be established (Boissy & Lamoreux, 1988). The well-documented Smyth chickens express 
a genetically inherited form of vitiligo-like depigmentation resulting from the loss of 
melanocytes in feather and ocular tissues (Smyth, 1989). In this avian model, vitiligo begins 
with an inherent melanocyte defect that is followed by an autoimmune response involving 
both humoral and cellular reactions that eliminate abnormal pigment cells (Boissy et al., 
1984; Boyle et al., 1987; Lamont & Smyth, 1981; Pardue et al., 1988). An increase in T cells in 
the feather pulp and circulating inflammatory leukocytes has been shown in Smyth chickens 
prior to the onset, and during the development of, vitiligo (Erf & Smyth, 1996; Erf et al., 
1995). Antibodies to chicken melanocytes have also been detected in the sera of 100% of 
Smyth chicks but not in the sera of normally pigmented birds (Austin et al., 1992). These 
antibodies were found to be present both before and during the presentation of vitiligo 
(Searle et al., 1991), and the primary target antigen was identified as the melanogenic 
enzyme tyrosinase-related protein-1 (Austin & Boissy, 1995). In other animals with vitiligo 
including horses, cats and dogs, antibody reactivity occurs against a similar pattern of 
melanocyte antigens to that found in patients with the disease (Naughton et al., 1983b; 
Naughton et al., 1986a), suggesting that similar immunological responses occur in both 
animals and humans.  
2.4 Vitiligo melanocytes 
Several studies have shown abnormal expression of MHC class II antigen HLA-DR and 
increased expression of intercellular adhesion molecule-1 by perilesional melanocytes in 
vitiligo compared with melanocytes from normal skin (Al Badri et al., 1993a; Hedley et al., 
1998; Van den Wijngaard et al., 2000). Since these molecules have important roles in antigen 
presentation and in the activation of helper T cells, their expression by melanocytes could 
contribute to the anti-melanocyte cellular immune responses that are seen in vitiligo (Ogg et 
al., 1998; Van den Boorne et al., 2009). Both vitiligo and normal melanocytes are also capable 
of expressing MHC class I molecules (Hedley et al., 1998), which could allow interaction 
with destructive cytotoxic T cells. Furthermore, melanocytes have an antigen processing and 
presenting capability which can make them target cells for T cell-mediated cytotoxicity (Le 
Poole et al., 1993b). In perilesional vitiligo biopsies, melanocytes express macrophage 
markers CD68 and CD36 (Van den Wijngaard et al., 2000) and reduced levels of membrane 
regulators of complement activation, including decay acceleration factor and membrane 
cofactor protein (Van den Wijngaard et al., 2002), which suggests a vulnerability of these 
cells to attack by macrophages and the complement system, respectively.  
2.5 Vitiligo treatments 
Repigmentation in vitiligo patients receiving treatment with immunosuppressive agents 
indirectly supports the theory that immune-mediated processes are involved in vitiligo 
pathogenesis. Topically applied tacrolimus (FK506), a therapeutic agent which exerts a 
potent immunosuppressive effect on T cells by blocking the action of the cytokine gene-
activating cofactor calcineurin (Homey et al., 1998), has resulted in successful 
repigmentation responses in vitiligo patients (Boone et al., 2007; Hartmann et al., 2008). 
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Topical corticosteroids, which have anti-inflammatory and immunosuppressive actions, are 
considered to be an effective first-line treatment in children and adults with segmental or 
non-segmental vitiligo of recent onset (Abu Tahir et al., 2010; Gawkrodger et al., 2010), and, 
indeed, following treatment of vitiligo patients with systemic steroids, a reduction in anti-
melanocyte antibody levels and in antibody-mediated anti-melanocyte cytotoxicity has been 
demonstrated (Hann et al., 1993; Takei et al., 1984). 
Psoralen with ultraviolet radiation (PUVA) is used as a second-line therapy for vitiligo 
(Alomar, 2010; Gawkrodger et al., 2010). Following PUVA treatment, a reduction in the 
number of Langerhans cells and a decrease in the expression of vitiligo-associated 
melanocyte antigens, which could lead to a blocking of antibody-dependent cell-mediated 
cytotoxicity against melanocytes, have been noted in vitiligo patients (Kao & Yu, 1992; Viac 
et al., 1997). In addition, ultraviolet radiation can induce the expression of anti-inflammatory 
cytokines, modulate the expression of intercellular adhesion molecule-1, and induce 
apoptosis of skin-infiltrating T lymphocytes (Duthie et al., 1999; Krutmann & Morita, 1999).  
2.6 Humoral immune responses 
2.6.1 Melanocyte antibodies   
Antibodies to melanocytes occur at a significantly increased frequency in the sera of vitiligo 
patients compared with healthy individuals (Cui et al., 1992; Cui et al., 1995; Farrokhi et al., 
2005; Hann et al., 1996a; Hann et al., 1996b; Naughton et al., 1983a; Naughton et al., 1983b; 
Rocha et al., 2002). As well as circulating antibodies, antibody deposits have been noted in 
the basement membrane zones of depigmented areas in patients with vitiligo (Uda et al., 
1984). However, no B cells or antibody has yet been isolated from vitiligo lesions. 
Interestingly, correlations can also exist between the incidence and level of melanocyte 
antibodies and both the activity and extent of vitiligo (Aronson & Hashimoto, 1987; Harning 
et al., 1991; Kemp et al., 2011; Naughton et al., 1986b; Yu et al., 1993), indicating that 
melanocyte antibodies are  possible markers of disease progression. 
Predominantly, melanocyte antibodies have been characterised as IgG (Cui et al., 1992; Cui 
et al., 1995; Farrokhi et al., 2005; Hann et al., 1996a; Hann et al., 1996b; Naughton et al., 
1983a; Naughton et al., 1983b; Rocha et al., 2002; Uda et al., 1984) and as belonging to 
subclasses IgG1, IgG2 and IgG3 (Xie et al., 1991), although anti-melanocyte IgA antibodies 
have also been reported (Aronson & Hashimoto, 1987). Initial immunoprecipitation studies 
using melanoma cell extracts revealed that antibodies in vitiligo patients were most 
commonly directed against antigens with molecular weights of 35, 40-45, 75, 90 and 150 kDa 
(Cui et al., 1992). Several of the proteins (40-45, 75 and 150 kDa) appeared to be common 
tissue antigens, while others (35 and 90 kDa) were preferentially expressed on melanocytes 
(Cui et al., 1992). In immunoblotting studies with melanocyte extracts, antigens of 45, 65, 
and 110 kDa have been identified (Hann et al., 1996b; Park et al., 1996), while vitiligo-
associated antibodies have been demonstrated to recognise melanoma cell proteins of 68, 70, 
88, 90, 110 and 165 kDa (Hann et al., 1996a; Rocha et al., 2002). 
The identity of several vitiligo-associated antibody targets has been reported and these are 
summarised in Table 3. Included are the melanogenic enzymes tyrosinase (Baharav et al., 
1996; Kemp et al., 1997a; Song et al., 1994) and tyrosinase-related protein-2 (Kemp et al., 
1997b; Okamoto et al., 1998), and the melanosomal matrix protein gp100 (Pmel17) (Kemp et 
al., 1998a). The technique of peptide phage-display has identified the melanin-concentrating 
hormone receptor 1 (MCHR1) and tyrosine hydroxylase as targets of vitiligo patient 
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antibodies (Kemp et al., 2002). Recent proteomic analysis has also revealed lamin A is a 
vitiligo-associated antigen (Li et al., 2010). 
 
Antigen Number of 
Patients with 
Antibodies (%) 
Number of 
Controls with 
Antibodies (%) 
Reference 
Lamin A 24/84 (28.6) 2/64 (3.1) Li et al., 2010 
MCHR1 9/55 (16.4) 0/28 (0) Kemp et al., 2002  
MCHR1 12/84 (14.3) Not reported Li et al., 2010 
Pmel17 3/53 (5.9) 0/20 (0) Kemp et al., 1998a  
SOX10 3/93 (3.2) 0/65 (0) Hedstrand et al., 2001  
SOX9 1/93 (1.1) 0/65 (0) Hedstrand et al., 2001  
Tyrosinase 16/26 (61) 0/31 (0) Song et al., 1994  
Tyrosinase 7/18 (39) 0/12 (0) Baharav et al., 1996  
Tyrosinase 5/46 (10.9) 0/20 (0) Kemp et al., 1997a  
TRP-1 3/53 (5.9) 0/20 (0) Kemp et al., 1998b  
TRP-1 8/84 (9.5) Not reported Li et al., 2010 
TRP-2 3/53 (5.9) 0/20 (0) Kemp et al., 1997b  
TRP-2 10/15 (67) 0/21 (0) Okamoto et al., 1998  
TRP-2 20/30 (67) 1/35 (2) Okamoto et al., 1998  
Tyrosine hydroxylase 18/79 (23) 0/28 (0) Kemp et al., 2011 
Table 3. Defined antibody targets in patients with vitiligo 
2.6.2 Pathogenic mechanisms  
With respect to pathogenic effects, vitiligo-associated antibodies are able to destroy 
melanocytes and melanoma cells in vitro and in vivo by complement-mediated damage and 
antibody-dependent cellular cytotoxicity (Fishman et al., 1993; Gottumukkala et al., 2006; 
Norris et al., 1998a). Complement-mediated cytolysis of melanocytes by vitiligo patient 
antibodies appears to be cell selective and more common in individuals with active disease 
(Cui et al., 1993). Passive immunisation of nude mice grafted with human skin has also 
indicated that IgG from vitiligo patients can induce melanocyte destruction (Gilhar et al., 
1995). Furthermore, IgG melanocyte antibodies from individuals with vitiligo can induce 
HLA-DR and intercellular adhesion molecule-1 expression on and release of interleukin-8 
from melanocytes (Yi et al., 2000). Such changes that may enhance the antigen-presenting 
activity of melanocytes allowing antigen-specific immune effector cell attack resulting in 
melanocyte destruction.  
Antibodies against MCHR1 have been shown to block the function of the receptor in a 
heterologous cell line (Gottumukkala et al., 2006). Stimulation of MCHR1 in cultured 
melanocytes with melanin-concentrating hormone (MCH) can down regulate the actions of 
-melanocyte-stimulating hormone, including the production of melanin, suggesting that 
the MCH/MCHR1 signalling pathway has a role with the melanocortins in regulating 
melanocyte function (Hoogduijn et al., 2002). Any adverse effects of MCHR1 antibodies 
upon the functioning of the receptor in melanocytes could potentially disrupt normal 
melanocyte behaviour, a feature that could precede the clinical manifestation of vitiligo. 
However, this has not yet been reported and is still the object of study. More recent work 
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has found that 69% (9/13) of vitiligo patient sera tested induced melanocyte detachment in a 
reconstructed epidermis model, although this was unrelated to either the extent or the 
activity of the disease (Cario-Andre et al., 2007). Further studies are needed to confirm that 
this serum effect is antibody mediated and, if so, that the antibody activity is specific to 
vitiligo patient sera. 
2.6.3 Other antibodies 
Circulating organ-specific autoantibodies, particularly to the thyroid, adrenal glands, gastric 
parietal cells, and pancreatic islet cells are commonly detected in the sera of vitiligo patients 
(Brostoff, 1969; Betterle et al., 1976; Mandry et al., 1996; Zauli et al., 1986). Moreover, 
antinuclear antibody and IgM-rheumatoid factor have been detected at a significant 
frequency in vitiligo patients (Farrokhi et al., 2005). Anti-keratinocyte intracellular 
antibodies that correlate with disease extent and activity have also been detected in vitiligo 
patients (Yu et al., 1993).  
2.7 Cellular immune responses 
2.7.1 Cytokines 
An imbalance of cytokines, which can affect melanocyte activity and survival, has been 
shown in vitiligo lesional skin (Moretti et al., 2002). The level of granulocyte-macrophage 
colony-stimulating factor is reduced in patients with active vitiligo compared with healthy 
controls (Yu et al., 1997; Moretti et al., 2002). This cytokine has been found to act as a growth 
factor for melanocytes and a decrease in its production slows down the proliferation of 
surviving melanocytes in vitiligo lesions (Imokawa et al., 1996). Other melanogenic 
cytokines, including stem cell factor and endothelin-1, are also lowered in depigmented 
lesions (Moretti et al., 2002). 
Serum levels of soluble interleukin-2 receptor can be used to monitor in vivo immune 
activation, and its elevation has been correlated with T cell-mediated immune disease. 
Indeed, the level of the soluble interleukin-2 receptor level in vitiligo patients is significantly 
increased compared with that of controls, indicating that the activation of T cells is a 
component in the pathogenesis of vitiligo (Tu et al., 1999; Yeo et al., 1999). The production of 
interleukin-6 by mononuclear cells is also elevated in vitiligo patients (Yu et al., 1997). This 
cytokine can induce the expression of intercellular adhesion molecule-1 on melanocytes 
thereby facilitating leukocyte-melanocyte interactions and consequently cause 
immunological damage (Kirnbauer et al., 1992). Increased production of interleukin-8, 
which can attract neutrophils to vitiligo lesions amplifying destructive inflammatory 
reactions, has also been reported in the mononuclear cells of vitiligo patients (Yu et al., 
1997). Furthermore, the expression of tumour necrosis factor-alpha, an inflammatory 
mediator involved in the pathogenesis of autoimmune disease, is significantly elevated in 
vitiligo skin (Moretti et al., 2002). However, the exact roles in vitiligo pathogenesis of these 
inflammatory cytokines, which can also act as paracrine inhibitors of melanocyte 
proliferation and of melanogenesis, remain to be determined. 
2.7.2 Macrophages 
Macrophage infiltration has been demonstrated in vitiligo lesions, with increased numbers 
present in perilesional skin (Le Poole et al., 1996; Van den Wijngaard et al., 2000). It is 
possible that macrophages are involved in clearing melanocytes that have been induced to 
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apoptose by cytotoxic T lymphocytes. Additional evidence for the active involvement of 
macrophages in vitiligo pathogenesis is demonstrated by their expression of 
immunoglobulin receptors: in a mouse model, it has been shown that macrophages, 
expressing the common gamma chain of the activating Fc gamma receptors, can mediate 
vitiligo in the presence and absence of complement C3 fraction (Trcka et al., 2002) 
2.7.3 Dendritic cells  
The density of Langerhans cells in vitiliginous skin has been variously reported as normal, 
increased and decreased compared with pigmented skin from the same patients and from 
control subjects (Claudy & Rouchouse, 1984; Hatchcome et al., 1987; Riley, 1967; Searle et al., 
1991). The differences in the documented Langerhans cells densities may be due to the type 
of vitiligo, the sampling techniques used or the site of skin biopsies. An increase in the 
number of Langerhans cells could contribute to the immunological processes that damage 
melanocytes. However, although degenerative changes in Langerhans cells have been 
observed in vitiligo skin lesions, their role in vitiligo still remains unclear. More recently, 
dendritic cell-mediated destruction of melanocytes has been demonstrated in vivo and in 
vitro (Kroll et al., 2005). This process is related to the release of heat-shock protein 70 by 
stressed melanocytes, which induces an immune response against the cells from which it is 
produced, and to the increased expression of tumour-necrosis factor-related apoptosis 
inducing ligand receptors on stressed melanocytes making them more prone to killing by 
dendritic cells (Denman et al., 2008; Kroll et al., 2005). 
2.7.4 T cells 
Autoimmune disorders are often associated with an expansion of peripheral helper T cells. 
However, with respect to vitiligo, inconsistent data regarding abnormalities in circulating 
helper T cells have been reported. An increase in the number of activated helper T cells was 
detected in patients with stable vitiligo as well as in their first-degree relatives when 
compared with healthy individuals (Abdel-Naser et al., 1992; D’Amelio et al., 1990; Soubiran 
et al., 1985). In contrast, a decrease in the helper T cell population has also been observed in 
individuals with vitiligo (Grimes et al., 1986; Halder et al., 1986). No simple explanation 
exists for these differences but they could be attributable to the factors such as the 
population of patients under study, disease characteristics and received treatments.  
Circulating melanocyte-specific cytotoxic T lymphocytes that target melanocyte-specific 
antigens, including Melan-A (MART-1), gp100 (Pmel17) and tyrosinase, have been detected 
in vitiligo patients (Lang et al., 2001; Ogg et al., 1998; Palermo et al., 2001). They express high 
levels of the skin-homing receptor cutaneous lymphocyte-associated antigen and their 
frequency correlates with both the extent and activity of the disease (Lang et al., 2001). In 
addition, melanocyte-specific T cells have cytotoxic reactivity towards melanocytes (Ogg et 
al., 1998). Such findings are consistent with a role for skin-homing, autoreactive, 
melanocyte-specific T cells in causing the destruction of melanocytes in vitiligo. 
Histological studies of skin biopsies from vitiligo patients have demonstrated that 
infiltrating cytotoxic and helper T cells are most prominent at the periphery of vitiligo 
lesions (Al Badri et al., 1993b; Van den Wijngaard et al., 2000). Many of the inflammatory 
cells are activated, as indicated by the expression of the MHC class II antigen HLA-DR, and 
a significant number also exhibit high levels of the receptor cutaneous lymphocyte-
associated antigen, typical of skin-homing T cells (Al Badri et al., 1993b; Van den Wijngaard 
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et al., 2000). Local activation of cytotoxic T cells at the perilesional epidermal/dermal 
junction of vitiliginous skin is also suggested by the presence of granzyme B+ and perforin+ 
cells (Van den Wijngaard, et al., 2000). There is evidence for interleukin-2 receptor and 
interferon-gamma receptor expression by the lymphocytic infiltrate (Abdel-Naser et al., 
1994), and also for down-regulation of the helper T cell 2-dependent CDw60 molecule in the 
vitiliginous epidermis suggesting that infiltrating T cells may exhibit a helper T cell 1-type 
cytokine production pattern which is consistent with cell-mediated organ-specific 
autoimmunity (Le Poole et al., 2003). In addition, perilesional T cell clones exhibit a 
predominant type-1-like cytokine secretion profile (Wankowicz-Kalinska et al., 2003). More 
recently it has been demonstrated that T lymphocytes obtained from perilesional skin 
biopsies are enriched for cytotoxic T cells that recognise melanocyte antigens tyrosinase, 
gp100 and MelanA (Van den Boorn et al., 2009). Moreover, upon infiltration of autologous 
pigmented skin, isolated perilesional T lymphocytes efficiently kill melanocytes, providing 
direct evidence that cytotoxic T cells can cause the depigmentation seen in vitiligo (Van den 
Boorn et al., 2009). Additional to this, are findings that regulatory T cells occur at a reduced 
level in the skin of vitiligo patients (Klarquist et al., 2010). This may allow the unchecked 
destruction of melanocytes by cytotoxic T cells in vitiligo lesions (Klarquist et al., 2010).  
3. Conclusion 
Autoimmunity is one hypothesis forwarded to explain the development of vitiligo due to 
the evidence presented in this review. However, it is most likely that interacting 
mechanisms, of which immune responses are a part, are responsible for the clinical 
manifestations of the disease (Le Poole et al., 1993a). In addition, although the evidence for 
the role of immune-related genes in the aetiology of vitiligo is clear, the limited concordance 
in identical twins (Alkhateeb et al., 2003) indicates that other factors, probably 
environmental, are also involved in its development, making the disease  complex, 
polygenic, and multi-factorial. Notably, in vitro studies have provided a link and a temporal 
sequence connecting cellular oxidative stress (Dell’Anna & Picardo, 2006; Schallreuter et al., 
1991; Schallreuter et al., 2001; Schallreuter et al., 2005) and the immune response in vitiligo: 
stressed melanocytes were found to mediate dendritic cell-activation with the consequent 
dendritic cell effector functions playing a role in the destruction of melanocytes (Kroll et al., 
2005). This work suggests that intrinsic damage to melanocytes could be the initiating event 
in vitiligo development followed by a secondary immune response by cytotoxic T cells 
which exacerbates the destruction of melanocytes and progresses the disease (Hariharan et 
al., 2010; Le Poole & Luiten, 2008; Van den Boorn et al., 2011). Indeed, 50% of vitiligo 
patients experience a Koebner phenomenon, whereby depigmented lesions develop at a site 
previously exposed to a physical stress (Le Poole & Luiten, 2008). 
As indicated, it is most likely that immune responses in vitiligo are of a secondary nature 
following melanocyte damage. Indeed, several vitiligo-associated autoantigens such as 
tyrosinase and gp100 are located intracellularly, and it has been suggested that either the 
formation of neo-antigens due to haptenation, the exposure of cryptic epitopes or the 
modification of proteins during apoptosis could account for immune responses to these 
molecules (Namazi, 2007; Westerhof & d’Ischia, 2007). Following processing by mature 
Langerhans cells, antigenic peptides could be presented to T cells which have escaped clonal 
deletion or to naïve T lymphocytes which have not been tolerised against cryptic epitopes 
(Namazi, 2007; Westerhof & d’Ischia, 2007). Antibodies could then be produced following 
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the stimulation of B lymphocytes by activated helper T cells (Namazi, 2007), and activated 
cytotoxic T cells could directly attack melanocytes expressing antigenic peptides on their 
surface in the context MHC class I molecules (Hedley et al., 1998; Le Poole et al., 1993b). In 
the case of immune reactivities against common cellular antigens, the selective destruction 
of melanocytes in vitiligo might occur because they are intrinsically more sensitive to 
immune-mediated injury than other skin cells (Norris et al., 1988b). 
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